This project has been flagged by a community member as inappropriate due to reason below.*

Expert Interview

Slingshot members are talking to an expert! The topic is:

Checking on the Launch of Xpovio in relapsed refractory multiple myeloma and relapsed or refractory diffuse large B-cell lymphoma

Ticker(s): KPTI

Who's the expert?

Institution: Regional Care Cancer Associates

  • Co-Chief, Myeloma Division, Director, Myeloma Research at the John Theurer Cancer Center, and Professor of Medicine at Hackensack Meridian School of Medicine.
  • Research focused on plasma cell dyscrasias (multiple myeloma, monoclonal gammopathy of undetermined significance, amyloidosis, Waldenstrom's macroglolinemia.
  • Member of the Stem Cell Transplant & Cellular Immunotherapy Program at Hackensack UMC and Medstar Georgetown University Hospital.

Interview Goal
This conversation will discuss real world experience treating patients with Xpovio

Are You Interested In These Questions?

Slingshot Insights Explained

Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.

Reason

*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.